This project is designed to prepare a GMP quality investigational multicomponent Ebola vaccine and complete the preclinical and laboratory studies needed to begin a clinical trial. The first clinical trial (VRC-204) is a Phase I, randomized, controlled, double-blinded, dose-escalation study to examine tolerability, dose, and immune response of the Ebola DNA plasmid vaccine. The hypothesis is that this vaccine will be safe for human administration and elicit immune responses to Ebola. Dose escalation will be initiated provided there are no significant adverse events in the previous dose level.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI005054-02
Application #
6987376
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2004
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code